A baby who had a stroke in utero, was treated with her own cord blood at Duke University. The cord blood had been stored from birth by a private cord blood bank. The director of the pediatric program at Duke believes that the cord blood cells help decrease inflammation in the section of the brain that was affected by stroke.
blood is blood that comes from the umbilical cords of babies, and
contains a significant amount of hematopoietic stem cells. Specialized
cord blood banks store this blood. Cord blood stem cells
are considered far superior to stem cells from bone marrow. Cord blood
of a baby is preserved in the event it may be needed at some point in
the future for treatment of possible cancer or genetic disease of the child
or the child's siblings. Numerous diseases have been treated with cord
blood. Information on cord blood and how it is collected, stored, and used, is available at CordBloodStocks.com.
have a few options when investing in the cord blood industry. They can own the
stocks of the cord blood banks, they can own the companies that use cord blood
to develop cures, or they can own companies that produce extraction and storage products.
WallStreetNewsNetwork.com has come up with a list of 20 companies
involved in the cord blood field.
One example is PerkinElmer, Inc. (PKI), which owns ViaCell, a
Cambridge, Massachusetts company which sells ViaCord, a product which is
used to preserve baby's umbilical cord blood. They also research and
other therapeutic uses of umbilical cord blood-derived and adult-derived
stem cells. The stock trades at 30 times earnings and pays a small yield of 0.6%.
Baxter International Inc. (BAX)
makes blood collection bags for umbilical cord blood and develop adult
stem-cell therapies. They also own a patent for assembling and methods
to process cord blood in a sterile fashion to avoid exposure to
bacterial contamination and to disburse the introduction of
cryopreservation solution into cord blood at a desired rate, thereby
avoiding damage or trauma to the cord blood cells. The stock has a price to earnings ratio of 18 and sports a generous yield of 2.9%.
(CELG) is a New Jersey company that is involved in the discovery,
production, and marketing of therapies designed to treat cancer and
immune-inflammatory-related diseases. They own LifeBank USA, a cord
blood bank. The stock has a PE of 46.
Inc. (AMGN) is also funding research into cord blood extraction,
preservation, and storage. The stock has a forward PE of 19 and
carries a decent yield of 2.0%.
For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.
Disclosure: Author did not own any of the above at the time the article was written.